Guangdong, China

Jinxi Liao

This inventor holds 1 USPTO granted patent. Top assignee: Chinese Academy of Sciences. Active years: 2016.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jinxi Liao: Innovator in Pharmaceutical Chemistry

Introduction

Jinxi Liao is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug compounds. His work focuses on enhancing the efficacy of anti-inflammatory and analgesic medications.

Latest Patents

Jinxi Liao holds a patent for "Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof." This invention discloses coupling compounds formed by connecting NSAID anti-inflammatory and analgesic drugs with EGFR inhibitors through ester bonds or pharmaceutically acceptable salts or stereoisomers. The patent highlights the potential applications of these compounds in improving therapeutic outcomes.

Career Highlights

Liao is affiliated with the Chinese Academy of Sciences, where he conducts research and development in pharmaceutical sciences. His innovative approach to drug synthesis has garnered attention in the scientific community. He has successfully developed a unique method for creating compounds that combine the benefits of NSAIDs and EGFR inhibitors.

Collaborations

Jinxi Liao has collaborated with notable colleagues, including Yanmei Zhang and Ke Ding. Their joint efforts have contributed to advancing research in the field of drug development.

Conclusion

Jinxi Liao's work exemplifies the intersection of innovation and pharmaceutical research. His contributions to drug synthesis and development are paving the way for new therapeutic options in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…